Extra Credit: S&P Global Ratings’ Public Finance Podcast

The S&P Pharma Dose - Episode 11: Four Takeaways - Eli Lilly

01.12.2017 - By S&P GlobalPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Analyst Arthur Wong discusses the ratings and outlook on Eli Lilly, in the wake of the company’s upbeat earnings guidance despite the recent loss of its high profile drug prospect, the Alzheimer’s treatment, solanezumab.

More episodes from Extra Credit: S&P Global Ratings’ Public Finance Podcast